{
  "retracted": false,
  "timestamp": 1592870400000,
  "updates": [
    {
      "timestamp": 1592894449186,
      "identifier": {
        "doi": "10.1007/s10637-020-00964-9"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1007/s10637-020-00916-3"
  },
  "publisher": "Springer Science and Business Media LLC",
  "title": "Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma"
}
